Vitamin D supplementation for cystic fibrosis.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a meta-analysis.

To assess the effects of vitamin D supplementation on the frequency of vitamin D deficiency, respiratory outcomes and vitamin D toxicity in the cystic fibrosis population.

Why It Was Studied

Cystic fibrosis (CF) is a genetic disorder with multiorgan effects.

In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins (A, D, E, K) may occur.

Who the Included Studies Covered

By PubMed's age tags, the people studied were children and adults.

How the Review Was Done

The researchers searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search: 08 July 2013.

What Was Measured

Both authors independently assessed the risk of bias of each included study and extracted outcome data (from published study information) for assessment of bone mineralization, growth and nutritional status, frequency of vitamin D deficiency, respiratory status, quality of life and adverse events.

Topics PubMed links to this paper include Bone Density Conservation Agents, Bone Diseases, Metabolic, Calcifediol, Calcitriol, Calcium, Dietary, Cystic Fibrosis and Dietary Supplements.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 16 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (The Cochrane database of systematic reviews), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.